17α-Hydroxylase deficiency

17α-Hydroxylase Deficiency is a rare genetic disorder that affects steroidogenesis, the process by which steroids are synthesized by the body. This condition is part of a group of disorders known as congenital adrenal hyperplasia (CAH), which involves the adrenal glands' inability to produce certain hormones. Specifically, 17α-Hydroxylase deficiency leads to a reduced production of the adrenal hormones cortisol and aldosterone, and an increase in the production of mineralocorticoids, which can cause an imbalance in electrolytes and blood pressure regulation.

Causes[edit | edit source]

17α-Hydroxylase deficiency is caused by mutations in the CYP17A1 gene, which encodes the enzyme 17α-hydroxylase. This enzyme is crucial for the production of cortisol in the adrenal cortex and sex steroids. Without functional 17α-hydroxylase, the synthesis of these hormones is impaired, leading to the accumulation of precursor molecules and a shift in the production towards mineralocorticoids.

Symptoms[edit | edit source]

The symptoms of 17α-Hydroxylase deficiency can vary but often include hypertension (high blood pressure) and hypokalemia (low potassium levels) due to the excess production of mineralocorticoids. Additionally, individuals with this condition may experience abnormal development of sexual characteristics. Affected genetic males (XY) may present with ambiguous genitalia or appear phenotypically female, while genetic females (XX) may experience delayed or absent menstruation and lack secondary sexual characteristics.

Diagnosis[edit | edit source]

Diagnosis of 17α-Hydroxylase deficiency typically involves a combination of clinical evaluation, biochemical tests, and genetic testing. Biochemical tests measure the levels of hormones in the blood or urine, revealing the characteristic pattern of low cortisol and sex steroids, and elevated mineralocorticoid levels. Genetic testing can confirm the presence of mutations in the CYP17A1 gene.

Treatment[edit | edit source]

Treatment for 17α-Hydroxylase deficiency focuses on correcting the hormone imbalances. This usually involves glucocorticoid replacement to reduce the production of ACTH and mineralocorticoids, thereby lowering blood pressure and correcting hypokalemia. Additionally, patients may require sex hormone replacement therapy to promote the development of secondary sexual characteristics and support normal sexual function.

Prognosis[edit | edit source]

With appropriate treatment, individuals with 17α-Hydroxylase deficiency can lead relatively normal lives. However, managing the condition requires lifelong monitoring and treatment adjustments, especially during periods of stress, illness, or major life transitions such as puberty, pregnancy, or aging.